Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

REPLIGEN CORP (RGEN) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

REPLIGEN CORP (RGEN), most recent 12 months reported: revenue $785.1M, net income $41.54M, free cash flow $110.15M. Latest balance sheet on file: liquid cash $810.45M, total debt $551.05M, net cash $259.4M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): QIAGEN N.V. · HALOZYME THERAPEUTICS, INC. · BIO-TECHNE Corp · BIOCRYST PHARMACEUTICALS, INC. · TARSUS PHARMACEUTICALS, INC. · ADMA BIOLOGICS, INC. · Krystal Biotech, Inc. · Twist Bioscience Corporation

Stock screener

Watchlist